A Phase 2 Study of HX301 in Patients with High-grade Giloma — Stella

stellabeta Find trials matched to me Trial Match

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Phase 2 Study of HX301 in Patients with High-grade Giloma — Stella

Recruiting

Back to Glioma trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

China

Beijing Tiantan Hospital Capital Medical University, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Hangzhou Hanx Biopharmaceuticals, Ltd.

Enrollment target

~72 participants

Started

January 2025

Primary completion

December 2026

Age range

18 Years and older

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov